Plozasiran · SHASTA-5
SHASTA-5 tests adjudicated acute pancreatitis as the primary endpoint. SHASTA-3/4 triglyceride and pooled pancreatitis results are already disclosed and do not settle this separate event-driven trial. plozasiran — phase 3 study in Severe Hypertriglyceridemia. NCT06880770 measures Time to First Occurrence of Positively Adjudicated AP Event (Event Occurring More Than 10 Days After First Dose of Study Drug) (Randomization up to end of Double Blind Treatment Period compared to placebo (Approximate Maximum 50 Months)]). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Event-driven pancreatitis study — date unconfirmed
Potential outcome market
Will plozasiran meet the prespecified primary endpoint in NCT06880770 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.